Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biodesix Buys US Laboratory Assets From Oncimmune

Executive Summary

Biodesix is expanding its portfolio of lung cancer diagnostic tests and acquiring the US assets of UK company Oncimmune.

You may also be interested in...



Breakthrough Status, Big Investments For Liquid Biopsies

The growth potential of liquid biopsy diagnostics is drawing increasing attention, with several recent breakthrough device designations from the US FDA, big funding rounds, and major acquisitions all in play.

Start-Up Snapshot: Alpha Tau Hopes For A Breakthrough In Radiotherapy

Start-Up Snapshot: Barcode Diagnostics, Personalized Cancer Drug Screening

Barcode Diagnostics is developing a nanotechnology for personalized cancer drug screening. The start-up’s aim is to provide physicians with a tool that matches patients with the most effective medicine, during the different stages of disease.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125307

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel